NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical...
Pharmaceutical
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences
Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of...
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences
Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of...
Stemtech Corporation – Stemtech Healthsciences India Pvt Ltd Announces Strategy for Market Entry
NAPLES, FL / ACCESS Newswire / October 27, 2025 / "STEMTECH CORPORATION", the global leader and pioneer in stem cell...
Curia Invests $4 Million to Enhance Sterile API Manufacturing
ALBANY, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading global research, development and manufacturing organization,...
Curia Invests $4 Million to Enhance Sterile API Manufacturing
ALBANY, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading global research, development and manufacturing organization,...
Curia Invests $4 Million to Enhance Sterile API Manufacturing
ALBANY, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading global research, development and manufacturing organization,...
Curia Invests $4 Million to Enhance Sterile API Manufacturing
ALBANY, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading global research, development and manufacturing organization,...
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a...
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a...
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a...
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a...
ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical...
ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical...
ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical...
Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing
Financing designed to support Phase 2 Parkinson’s trial and accelerate Nugevia™ product line growth Jupiter, FL, Oct. 27, 2025 (GLOBE...
Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing
Financing designed to support Phase 2 Parkinson’s trial and accelerate Nugevia™ product line growth Jupiter, FL, Oct. 27, 2025 (GLOBE...
Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing
Financing designed to support Phase 2 Parkinson’s trial and accelerate Nugevia™ product line growth Jupiter, FL, Oct. 27, 2025 (GLOBE...
Branded Legacy, Inc. Advances Revolutionary Intranasal Drug Delivery with Unitary Device Mold Development
Pioneering Precision Engineering to Transform Global Therapeutics DeliveryVANCOUVER, British Columbia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded...
Branded Legacy, Inc. Advances Revolutionary Intranasal Drug Delivery with Unitary Device Mold Development
Pioneering Precision Engineering to Transform Global Therapeutics DeliveryVANCOUVER, British Columbia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded...